ANNUAL REPORT 2021
LUNDBECK
ANNUAL REPORT 2021
= CONTENTS
Products
MATURE BRANDS
28 filmovertrukne tabletter
Cipralex 10 mg
escitalopram
Filmoverzuine fablecher
-
90 Capsules
NDC 67316-121-19
Northera
(drop capsules
200 mg
Pirty
16276
Onfi
(clobazam) Tablets
10 mg @
THE
Bus
TH
Sabril
(vigabatrin)
Tablets
500 mg
CipralexⓇ/Lexapro®
(escitalopram)
Indicated for the treatment of depression. First
launched in 2002 and today available in more
than 100 countries around the world.
Northera®
(droxidopa)
Indicated for the treatment of symptomatic
neurogenic orthostatic hypotension in adult
patients. NortheraⓇ is the only U.S.
FDA-approved therapy for this condition.
Lundbeck markets NortheraⓇ in the U.S.
and launched the product in 2014.
Onfi®
(clobazam)
Indicated as adjunctive treatment of
Lennox-Gastaut syndrome for people aged
two years or older. Launched in the U.S. in
2012.
SabrilⓇ
(vigabatrine)
Indicated for the treatment of refractory
complex partial seizures (rCPS) and infantile
spasms (IS). Launched in the U.S. in 2009.
Other pharmaceuticals
Ebixa (dementia), Azilect (Parkinson's
disease), Xenazine (chorea), DeanxitⓇ
(depression), Cipramil® (depression and
anxiety) and Cisordinol (psychosis) are
among the biggest of our other mature
brands.
REVENUE (DKKm)
2,346
% OF TOTAL REVENUE
14%
▼1%
REVENUE (DKKm)
665
% OF TOTAL REVENUE
4%
▼74%
REVENUE (DKKm)
505 21%
REVENUE (DKKm)
657 15%
REVENUE (DKKm)
2,439
▼11%
% OF TOTAL REVENUE
3%
% OF TOTAL REVENUE
4%
% OF TOTAL REVENUE
15%
31/111View entire presentation